SEC Comment Letter for Akari Therapeutics Plc (AKTX) (CIK 0001541157) (AKTX) — Oct 24, 2019
Akari Therapeutics Plc (AKTX) (CIK 0001541157)
Date: Oct. 24, 2019 · CIK: 0001541157 · Accession: 0000000000-19-014828
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234219
Letter
October 24, 2019 Clive Richardson Chief Executive Officer Akari Therapeutics Plc 75/76 Wimpole Street London W1G 9RT Re:Akari Therapeutics Plc Registration Statement on Form F-1 Filed October 15, 2019 File No. 333-234219 Dear Mr. Richardson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gregory Dundas at (202) 551-3436 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary Emmanuel, Esq.
Show Raw Text
October 24, 2019
Clive Richardson
Chief Executive Officer
Akari Therapeutics Plc
75/76 Wimpole Street
London W1G 9RT
Re:Akari Therapeutics Plc
Registration Statement on Form F-1
Filed October 15, 2019
File No. 333-234219
Dear Mr. Richardson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Gregory Dundas at (202) 551-3436 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Gary Emmanuel, Esq.